Guy Barry, Ph.D
Director, CEO
Guy is a director and co-founder at OncoLife Therapeutics. He was instrumental in conceiving and creating the bioinformatic platform that underlies target discovery and the ageing projects. Guy brings extensive experience to OncoLife both in laboratory science and biotechnology.
He comes from running his own laboratory of Neurogenomics at QIMR Berghofer in Brisbane where he focussed on making conceptual leaps in our understanding of human biology. His pioneering work investigating non-coding RNA and human stem cells motivated the idea of finding unique strategies to protect normal stem cells from cancer drugs.
Prior to heading his own laboratory, Guy performed post-doctoral work at the Queensland Brain Institute (Brisbane), the Institute for Molecular Bioscience (Brisbane), and the Garvan Institute (Sydney). He completed undergraduate studies at the University of Cape Town in South Africa before moving to The Scripps Research Institute in San Diego. A year later he joined a start-up biotechnology company, Neurocrine Biosciences Inc, where he stayed for 9 years as a Research Scientist.
Paul Baldock, Ph.D
Director, CSO
Paul is a director and co-founder of OncoLife Therapeutics, and brings 30 years of experience in the modelling of human disease and therapy development using murine models. His research has spanned metabolism, musculoskeletal neuroscience, and most recently cancer. Leading his own laboratory at The Garvan Institute of Medical Research in Sydney, Australia for the last 17 years, he has developed a wide range of murine models to recapitulate human disease processes in mice, including pharmacological, genetic, surgical and viral modalities, authoring over 100 scientific papers.
He is best known for cross-system studies, which have defined complex interactions between different organ systems in both health and disease. Demonstrating, for example, that whole body metabolism is defined by intricate inter-organ regulatory systems, and highlighting that guided intervention can induce positive responses in numerous organ systems. This multi-system phenotyping will enable precise side-effect and toxicity profiling of our oncology pipeline. Prior to arriving at the Garvan Institute, Paul completed a PhD in Human Physiology at the University of Adelaide. He holds A/Prof appointments at The University of Notre Dame, Australia and The University of New South Wales, Australia.